Intradiscal steroids. A prospective double-blind clinical trial

Area of Science:

• Orthopedics
• Pain Management
• Spinal Surgery

Background:

• Internal disc disruption and nuclear prolapse cause significant low back pain.
• Intradiscal therapies are explored for managing discogenic pain.
• Steroid injections are a common treatment modality for inflammatory conditions.

Purpose of the Study:

• To evaluate the clinical efficacy of intradiscal steroid injections.
• To compare methylprednisolone with bupivacaine for discogenic pain.
• To determine if intradiscal steroids offer a significant benefit over placebo for specific lumbar disc pathologies.

Main Methods:

• Prospective, randomized, double-blind study design.
• Inclusion criteria: one-level disc disruption/prolapse, positive discography response.
• Exclusion criteria: multilevel disease, stenosis, prior surgery, systemic steroid use.
• 25 patients randomized to methylprednisolone (Depo-Medrol) or bupivacaine (Marcaine).
• Pain assessment using pain diagram grid, visual analog scale, and Oswestry Pain Questionnaire pre- and post-injection.

Main Results:

• Methylprednisolone group (14 patients): 21% subjective improvement, 79% no improvement.
• Bupivacaine group (11 patients): 9% clinical improvement, 91% no improvement.
• No patients in either group showed clinical worsening.
• No statistically significant difference in outcomes between the two treatment groups.

Conclusions:

• Intradiscal steroid injections (methylprednisolone) did not demonstrate a statistically significant clinical benefit for patients with internal disc disruption or nuclear prolapse.
• Bupivacaine also showed minimal improvement, suggesting limited efficacy for these conditions via intradiscal administration.
• Further research may be needed to explore alternative or multimodal treatment strategies for discogenic pain.